US2011287048A1PendingUtilityA1

Antigen Specific Tregs and related compositions, methods and systems

39
Individually held — no corporate assignee on recordPriority: May 20, 2010Filed: May 20, 2011Published: Nov 24, 2011
Est. expiryMay 20, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:June L. RoundSarkis K. Mazmanian
A61P 37/06A61P 5/16A61P 31/14A61P 37/02A61P 9/00A61P 3/10A61P 5/14A61P 29/00A61P 27/02C12N 2501/90A61K 39/0008A61K 2039/6087A61K 35/12A61P 1/04A61P 25/00A61P 17/00A61P 21/04A61P 1/00A61P 19/02A61P 1/16A61K 40/4512A61K 40/22A61K 40/11C12N 5/0637
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen.

Claims

exact text as granted — not AI-modified
1 . A method to generate an antigen specific anti-inflammatory regulatory T cell, the method comprising contacting either:
 a) a T cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen; or   b) an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen.   
     
     
         2 . The method of  claim 1 , wherein the polysaccharide is PSA. 
     
     
         3 . The method of  claim 1 , wherein the T cell is a regulatory T cell. 
     
     
         4 . The method of  claim 1 , further comprising for b) contacting the antigen presenting cell, after said antigen presenting cell contacting with the zwitterionic polysaccharide conjugated to the antigen, with a regulatory T cell. 
     
     
         5 . The method of  claim 1 , wherein for b) contacting an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen is performed in presence of the regulatory T cell. 
     
     
         6 . The method of  claim 1 , wherein the zwitterionic polysaccharide is conjugated to the antigen by inclusion of the zwitterionic polysaccharide and the antigen on or within a same vesicle. 
     
     
         7 . The method of  claim 6 , wherein the vesicle is an OMV. 
     
     
         8 . The method of  claim 1 , wherein the zwitterionic polysaccharide is conjugated to the antigen by physical connect. 
     
     
         9 . The method of  claim 1 , wherein the zwitterionic polysaccharide is conjugated to the antigen by direct or indirect covalent linkage. 
     
     
         10 . The method  claim 1 , wherein the pro-inflammatory response is a cell mediated inflammatory response. 
     
     
         11 . The method of  claim 1 , wherein the pro-inflammatory response is a humoral inflammatory response. 
     
     
         12 . The method of  claim 1 , wherein the contacting is performed in vitro. 
     
     
         13 . The method of  claim 1 , wherein the T cells are obtained from an individual patient. 
     
     
         14 . The method of  claim 13 , wherein the generated antigen specific anti-inflammatory regulatory T cells are injected back into said individual. 
     
     
         15 . The method of  claim 1 , wherein the contacting is performed in vivo. 
     
     
         16 . The method of  claim 15 , wherein the contacting is performed by topical or systemic administration of the zwitterionic polysaccharide conjugated to the antigen to allow generation of the antigen specific T reg in the gut of an individual. 
     
     
         17 . The method of  claim 1 , wherein the antigen is associated with a condition selected from the group consisting of rheumatoid arthritis; myocarditis; scleroderma. type I diabetes, multiple sclerosis, Crohn's disease, ulcerative colitis; Sjorgens syndrome; Hashimoto's thyroiditis; Graves Disease; autoimmune hepatitis; and myasthenia gravis. 
     
     
         18 . A method of inhibiting antigen specific inflammation in an individual, the method comprising treating the individual with a zwitterionic polysaccharide conjugated to a specific antigen for a time and under conditions to induce an antigen specific anti-inflammatory regulatory T cell in the individual. 
     
     
         19 . The method of  claim 18 , wherein the polysaccharide is PSA. 
     
     
         20 . The method of  claim 18 , wherein the zwitterionic polysaccharide is conjugated to the antigen by inclusion of the zwitterionic polysaccharide and the antigen on or within a same vesicle. 
     
     
         21 . The method of  claim 18 , wherein the zwitterionic polysaccharide is conjugated to the antigen by physical connect. 
     
     
         22 . The method of  claim 18 , wherein the zwitterionic polysaccharide is conjugated to the antigen by direct or indirect covalent linkage. 
     
     
         23 . The method of  claim 18 , wherein the antigen is associated with a condition selected from the group consisting of rheumatoid arthritis; myocarditis; Scleroderma. Type I diabetes, multiple sclerosis, Crohn's disease, ulcerative colitis. Sjorgens syndrome, Hashimoto's thyroiditis, Graves Disease, autoimmune hepatitis, and myasthenia gravis. 
     
     
         24 . A method to generate an antigen specific anti-inflammatory regulatory T cell, the method comprising contacting either:
 a) a T cell with a zwitterionic polysaccharide for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen; or   b) an antigen presenting cell with a zwitterionic polysaccharide for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen.   
     
     
         25 . The method of  claim 24 , wherein the polysaccharide is PSA. 
     
     
         26 . The method of  claim 25 , wherein the zwitterionic polysaccharide is within or on the cell surface of a vesicle. 
     
     
         27 . The method of  claim 26 , wherein the vesicle is an OMV. 
     
     
         28 . The method of  claim 24 , wherein the zwitterionic polysaccharide is conjugated to an antigen. 
     
     
         29 . The method of  claim 24 , wherein the contacting is performed in vitro. 
     
     
         30 . The method of  claim 24 , wherein the generated an antigen specific regulatory T cells are injected into a patient.

Join the waitlist — get patent alerts

Track US2011287048A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.